A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Inclusion Criteria

• BMI greater than or equal (>=) to 27 kilogram per meter square (kg/m^2)
• Subjects able and willing to comply with a reduced-calorie diet and an increased physical activity program
• Age >= to 40 years with established CV disease as defined by one of the following:
• History of documented MI or ischemic stroke
• History of peripheral artery disease
• History of revascularization (coronary, carotid, or peripheral artery)
• Significant unrevascularized coronary arterial stenosis

OR

Age >= to 55 years for women or >= to 50 years for men who have type 2 diabetes mellitus (T2DM) without established CV disease plus at least one of the following CV risk factors:

• Hypertension, or currently receiving therapy for documented hypertension
• Dyslipidemia, or currently taking prescription lipid-lowering therapy for documented dyslipidemia
• Estimated glomerular filtration rate >= to 30 to less than equal ( = 30 ug/mg

Subjects with T2DM may have a pre-existing or new diagnosis of T2DM. A new diagnosis of T2DM (ie, discovered at Screening) should be based on the 2013 American Diabetes Association (ADA) guidelines.

All T2DM subjects must have an HbA[1c] less (<) than 10% at Screening. If subjects are being treated, or upon diagnosis need to be treated with antidiabetic agents, the T2DM treatment regimen must be stable for at least 3 months prior to randomization.

Exclusion Criteria

• Moderate or greater symptoms of congestive cardiac failure (New York Heart Association [NYHA] class III or IV)
• Known left ventricular (LV) ejection fraction < than 20%
• Moderate or greater symptoms of pulmonary hypertension (PH)
• Known severe valvular disease
• Moderate renal impairment, severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m^ per the CKD-EPI equation based on ideal body weight), or end stage renal disease (ESRD)
• Severe hepatic impairment
• Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations
• Use of more than one other serotonergic drug
• Use of drugs known to increase the risk for cardiac valvulopathy within 6 months prior to Screening including, but not limited to: pergolide, ergotamine, methysergide, cabergoline
• History or evidence of clinically significant disease (e.g., malignancy, cardiac, respiratory, gastrointestinal, renal or psychiatric disease)
• Use of lorcaserin HCl prior to Screening or hypersensitivity to lorcaserin HCl or any of the excipients
• Planned bariatric surgery
• Females must not be breastfeeding or pregnant